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ABSTRACT
The focal adhesion protein Tensin4, also known as cten (c-terminal tensin like), is 
structurally distinct from the three other members in the Tensin family. Its expression 
and potential functions in cancers including hepatocellular carcinoma (HCC) are 
not well understood. With immunohistochemistry, 43% (13/30) of our human 
HCC cases showed up-regulation of Tensin4 as compared with their corresponding 
non-tumorous livers. In HCC cells, treatment with epidermal growth factor (EGF) 
significantly induced Tensin4 transcript and protein expression, while treatment with 
pharmacological inhibitors against the MEK1/2 kinases abolished such induction, 
suggesting that Tensin4 expression was dependent on Ras/MAPK signaling. With 
immunofluorescence microscopy, the focal adhesion localization of Tensin4 was 
confirmed in HCC cells. Significantly, detailed examination using a panel of Tensin4 
deletion constructs revealed that this specific focal adhesion localization required 
the N-terminal region together with the C-terminal SH2 domain. Up-regulation of 
ERK signaling by EGF in the HCC cells resulted in a change to a mesenchymal cell-
like morphology through modulation of the actin cytoskeleton. Functionally, stable 
Tensin4 knockdown in SMMC-7721 HCC cells resulted in reduced cell proliferation 
and migration in vitro. Taken together, our data suggest that Tensin4 may play a 
pro-oncogenic role in HCC, possibly functioning as a downstream effector of Ras/
MAPK signaling.
INTRODUCTION
Focal adhesions are structural links between the 
extracellular matrix (ECM) and actin cytoskeleton [1]. 
Focal adhesions are composed of diverse molecules, for 
instance, receptors, structural proteins, adaptors, GTPase, 
kinases and phosphatases. These focal adhesion proteins 
play critical roles in normal physiological events such as 
cellular adhesion, movement, cytoskeletal structure and 
intracellular signaling pathways. In cancers, aberrant 
expression and altered functions of focal adhesion 
proteins contribute to adverse tumor behavior [2-6]. We 
have previously shown that focal adhesion proteins play 
critical roles in hepatocellular carcinoma (HCC) [7-9]. 
Understanding the molecular interactions and mechanisms 
of the interconnected focal adhesion proteins is of 
particular importance in understanding the mechanisms 
underlying HCC progression and development of potential 
effective treatment. 
The tensin family comprises four proteins, tensin-1, 
-2, -3, and -4 (also known as cten), which are involved 
in cell migration and are localized to focal adhesion 
sites [1]. All four tensin family members contain the Src 
homology 2 (SH2) and phosphotyrosine binding (PTB) 
domains at the C-terminus. Through the PTB domain, 
tensins bind to the cytoplasmic tail of beta integrins 
which are transmembrane cell-adhesion molecules [10]. 
Growing evidence suggests that tensin proteins are 
not just structural proteins but also act as an important 
link between the ECM, actin cytoskeleton and signal 
transduction. Although independent studies have reported 
the downregulation of tensin members in various human 
cancer cell lines and tissues [9, 11-13], yet the mechanism 
underlying the role of tensins in cancers is far from clear. 
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Tensin4 has drawn special attention in recent years due 
to its conserved SH2 and PTB domains at its c-terminus 
but lacks the N-terminus actin binding domain, making it 
structurally distinct from other tensins [1]. 
Tensin4 has been suggested to have oncogenic 
functions in some cancers and tumor-suppressor functions 
in others. It was shown to interact with RhoGAP DLC1 
(Deleted in Liver Cancer 1) via its SH2 domain through 
an atypical, phospho-tyrosine-independent manner and 
strongly regulates the localization and tumor suppressive 
action of DLC1 [14]. In contrast, there is growing 
evidence supporting that Tensin4 promotes cell migration 
whereas knocking down of Tensin4 reduces cell migration, 
implicating its potential role in cancer metastasis [15-17]. 
Tensin4 stimulates cell motility through displacement of 
tensin3 at focal adhesions and consequent dissociation 
between the cytoplasmic tails of integrin molecules 
and actin fibers in a very specific MCF10A breast line 
[17]. Furthermore, several groups have found it to be 
overexpressed in breast [17, 18], gastric [19], colonic 
[15, 16] cancers, but under-expressed in prostatic [20] 
and renal carcinoma [12]. However, the expression and 
functions of Tensin4 in HCC have not been reported. In 
this study, we explored the expression, its regulation and 
the potential functional role of Tensin4 in HCC cells.
RESULTS
Expression of Tensin4 in HCC cells and human 
HCCs
To examine the expression of Tensin4 in HCC cells, 
primer pairs specifically amplifying Tensin4 but not the 
other Tensin family members (Tensin1-3) were employed 
for qPCR assay (Figure 1A). The Tensin4 expression 
was examined in a panel of HCC cell lines. The relative 
Tensin4 expression was normalized to the internal control 
tubulin and the normalized expression level was then 
compared with the immortalized normal liver cells MIHA 
[22] (Figure 1B). High level of Tensin4 expression was 
observed in LO2 and SMMC-7721 cells, while similar 
expression level was observed in a subset of HCC cells 
(SK-Hep1, Hep3B, 97L and 97H) when compared to 
MIHA. The Tensin4 expression was low in the remaining 
HCC cells and marginally detectable in the SNU-series 
of HCC cells tested. To have a better understanding on 
how Tensin4 transcript expression correlated with that of 
the other Tensin members, Tensin1, -2 and -3 expression 
were detected in HCC cells with specific qPCR assays 
in the same panel of HCC cells (Supplementary Figure 
1A and B). Regression analysis of the expression data 
among individual Tensin members with Tensin4 revealed 
a positive correlation between Tensin1 and Tensin4 (R2 
= 0.3134, p = 0.03). No significant correlations were 
found among the Tensin2, -3 and -4 expression. With 
the use of Tensin4-specific antibodies recognizing the 
Tensin4 PTB domain as epitope (Supplementary Figure 
2), we observed the protein expression pattern of Tensin4 
was comparable to the transcript expression in HCC 
cells (Figure 1D). Similarly, comparable transcript and 
the corresponding protein expression was also observed 
for Tensin3 in HCC cells (Supplementary Figure 1C). 
With immunohistochemistry on a cohort of 30 randomly 
selected, surgically resected primary HCC samples from 
patients (Supplementary Table 1), overexpression of 
Tensin4 in HCCs, as compared with their corresponding 
non-tumorous livers, was found in 43% (13/30) of the 
cases (Figure 1E). 
The SH2 domain and the N-terminal region 
together were important for proper Tensin4 focal 
adhesion localization in HCC cells
Although Tensin4 is structurally distinct from other 
Tensin family members, it possesses the characteristic 
focal adhesion localization. However, the contribution 
of individual structural domains to this subcellular 
localization is unclear. To answer this, we cloned a 
panel of expression constructs that drove the expression 
of N-terminal GFP-fusion Tensin4 with its functional 
domains being removed individually or in combination 
(Figure 2A). The expression constructs were then 
transfected into HLE cells which had low endogenous 
Tensin4 expression. Successful expression of the specific 
Tensin4 variants was confirmed by Western blotting, 
showing protein bands of expected molecular size (Figure 
2B). 
With confocal microscopy, we observed that GFP-
Tensin4 showed a punctate staining in the cytoplasm 
perfectly co-localizing with the focal adhesion marker, 
paxillin. This focal adhesion localization partially required 
the presence of SH2 domain, as Tensin4 variants ∆SH2 
and ∆SH2PTB lacking the SH2 domain were less localized 
to the focal adhesions. Focal adhesion localization was 
not affected without the PTB domain, as demonstrated 
by the ∆PTB mutant (Figure 2C, upper part). Expression 
of GFP-SH2 and -PTB alone or -SH2-PTB showed non-
specific cellular staining resembling the GFP (Figure 2C, 
middle part). In contrast, the Tensin4 223-stop variant, 
which contained the central region in addition to the SH2-
PTB domain, showed focal adhesion localization as well 
as unexpected nuclear localization. The most N-terminal 
Tensin4 variant 1-223 showed actin-like localization in 
the cytoplasm, suggesting that it played a critical role 
in maintaining the cytoplasmic localization of Tensin4 
(Figure 2C, lower part). To further evaluate the relative 
importance of the N-terminal region and the C-terminal 
SH2 domain in contributing the focal adhesion localization 
of Tensin4, we quantified the focal adhesion localization 
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Figure 1: Tensin4 expression in HCC cells. A. Specificity of the Tensin4 specific primers for qPCR assay. B. qPCR assay for Tensin4 
transcript expression in HCC cell lines. Tubulin was served as the internal control. The normalized Tensin4 expression in each cell was 
displayed and compared with the immortalized liver cells MIHA. C. The mRNA expression levels of Tensin1, Tensin2 and Tensin3 in 
HCC cells in (B) were determined and subjected to regression analysis for their correlation with Tensin4 mRNA expression. The R2 and 
p values of their expression correlation were shown. D. Western blotting for Tensin4 expression in HCC cell lines. β-actin served as the 
normalization control. E. Immunohistochemistry showing overexpression of Tensin4 in three representative HCCs as compared with the 
corresponding non-tumorous (NT) livers.
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Figure 2: SH2 domain was required for the focal adhesion localization of Tensin4. A. Schematic diagram showing the 
structure of the N-terminal GFP-tagged Tensin4 expression constructs with specific functional domain being removed for the subsequent 
subcellular localization analysis. B. The Tensin4 constructs listed in (A) were transiently transfected in HLE cells and the cell lysates 
were subjected for western blotting against anti-GFP antibodies. C. The localization of various GFP-Tensin4 proteins was examined by 
confocal microscopy. The coverslips were counterstained with paxillin and DAPI for focal adhesions and cell nuclei. Scale bar: 10 μm. 
D. The percentages of the positive focal adhesion localization of a subset of GFP-Tensin4 mutant were quantified by counting as least 50 
transfected HLE cells. The mean values and corresponding SDs were obtained from three independent experiments.
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pattern among the Tensin4∆SH2, 1-223 and 223-stop with 
respect to the wild type control in HLE transfected cells 
(Figure 2D). Our data suggested that C-terminal SH2 
region played a significant role in determining the focal 
adhesion localization of Tensin4. Besides, the N-terminal 
region might also play an auxiliary role in supporting this 
localization with the observation that N-terminal region 
also showed only a certain percentage of focal adhesion 
localization, while lacking this N-terminal region slightly 
reduced the degree of this localization (Figure 2D). Taken 
together, focal adhesion targeting Tensin4 required more 
than just the SH2 domain and likely involved also the 
N-terminal region.
Tensin4 expression was up-regulated by EGF in a 
MAPK-dependent manner
The expression of Tensin4 in HCC cells led us 
to speculate the possibility of its regulation under the 
mitogen stimulation. We treated the SMMC-7721 and 
LO2 cells, which had good expression of Tensin4, with 
EGF, followed by detection of Tensin4 protein expression 
in a time course manner. Successful EGF treatment 
was indicated by the EGFR activation. The EGFR band 
shifted upward 5 minutes after stimulation and was 
gradually inactivated through protein down-regulation 
at the later time points. Importantly, the Tensin4 level 
was progressively up-regulated after EGF treatment and 
the protein expression level reached the maximum at 8 
Figure 3: EGF-induced Tensin4 up-regulation required ERK1/2 activation followed by transcription- and translation-
dependent mechanisms. A. SMMC-7721 and LO2 cells were treated with EGF at a concentration of 40 ng/ml for the indicated duration. 
The cell lysates were then collected and subjected to Western blotting for the indicated proteins. B. SMMC-7721 and LO2 cells were pre-
treated with an MEK inhibitor U0126 for 1 hour prior to EGF treatment for 6 hours. The cell lysates were then collected and subjected to 
Western blotting for the indicated proteins. C. SMMC-7721 and LO2 cells were pre-treated with MEK inhibitor U0126 for 1 hour prior 
to EGF treatment for 1 and 6 hours, respectively. The Tensin4 mRNA transcript level was determined by qPCR with normalization to 
tubulin. D. SMMC-7721 and LO2 cells were pre-treated with either transcriptional inhibitor Actinomycin D (ActD) or translational blocker 
Cycloheximide (CHX) for 1 hour prior to EGF treatment for 6 hours. The cell lysates were then collected and subjected to Western blotting. 
E. The Tensin4 mRNA transcript level was determined by qPCR with normalization to tubulin in SMMC-7721 and LO2 cells and subjected 
to treatment in (D).
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hours (Figure 3A). To understand the signaling underlying 
the EGF-induced Tensin4 expression in HCC cells, we 
examined the activation status of the two best known 
downstream pathways of receptor tyrosine kinase, the Ras-
MAPK and PI3K-Akt signaling. Interestingly, upon EGF 
treatment, the phospho-ERK1/2 activity was strongly and 
persistently up-regulated throughout the experiment, while 
the total ERK1/2 levels remained unaltered. In contrast, 
the phospho-Akt level was only transiently up-regulated 
in both cells. Pre-treatment with the pharmacological 
MEK inhibitor U0126 in both SMMC-7721 and LO2 cells 
markedly diminished the EGF-induced Tensin4 protein 
up-regulation (Figure 3B), showing that the expression 
of Tensin4 was strongly dependent on the phospho-
ERK1/2 activity. Pre-treatment with Rapamycin, which 
acts against the PI3K-Akt downstream, mTORC1, could 
not block the EGF-induced Tensin4 protein up-regulation 
(Supplementary Figure 3). We further confirmed these 
observations at the transcript level by showing the robust 
up-regulation of Tensin4 mRNA level in SMMC-7721 and 
LO2 cells upon EGF induction, while U0126 treatment 
consistently suppressed the increase in Tensin4 mRNA 
levels (Figure 3C). To further determine that the EGF-
induced Tensin4 expression was mediated by mRNA 
transcription followed by protein translation, we pre-
treated the SMMC-7221 and LO2 cells with either the 
transcriptional inhibitor Actinomycin D (ActD) or the 
translational blocker Cycloheximide (CHX), followed 
by Tensin4 mRNA and protein detection. qPCR analysis 
showed that both the basal and EGF-induced Tensin4 
mRNA expression levels were effectively suppressed 
by ActD treatment, while CHX treatment led to a slight 
up-regulation of basal Tensin4 mRNA transcript (Figure 
3D). Nevertheless, both treatments effectively blocked 
the EGF-induced Tensin4 protein up-regulation (Figure 
3E). Collectively, these observations suggested the EGF-
induced Tensin4 expression involved the de novo Tensin4 
mRNA transcription and protein translation.
Persistent ERK1/2 activation was required for 
EGF-induced Tensin4 expression
In SMMC-7721 cells, we noticed that transient EGF-
treatment as short as 5 minutes, followed by incubation 
in the absence of EGF till the 8-hour time point, was 
sufficient to trigger the signaling required for up-regulating 
Tensin4 expression. Notably, the increased length of EGF 
treatment only inversely correlated with the level of EGFR 
but did not affect the degree of ERK activation and the 
final Tensin4 protein expression level (Figure 4A). This 
observation prompted us about the possible importance of 
persistent ERK1/2 in triggering the Tensin4 up-regulation. 
To demonstrate that persistent ERK1/2 activity was 
required for EGF-induced Tensin4 up-regulation, we 
speculated that blocking the ERK1/2 activation by U0126 
at designated time points after EGF induction would 
diminish the Tensin4 up-regulation. Consistent to what we 
had shown in Figure 3B, pre-treatment of U0126 blocked 
the EGF-induced Tensin4 induction. Importantly, we 
found that addition of U0126 at early time points (ranging 
from 5 to 240 minutes) after EGF treatment effectively 
lowered the pERK1/2 activity, which was followed by 
the Tensin4 induction, in both SMMC-7721 and LO2 
cells (Figure 4B, upper and lower panel). Interestingly, 
although U0126 addition at 300 minutes (60 minutes 
before the experimental endpoint of EGF induction) 
could transiently suppress pERK1/2 activity, its effect in 
suppressing Tensin4 induction was not obvious, probably 
because the requirement of the persistent ERK1/2 
activation had been fulfilled in the first 300 minutes of 
the EGF treatment. To further examine whether EGF 
treatment was sufficient to upregulate Tensin4 expression 
in HCC cells with relatively low Tensin4 expression, PLC 
(very low expression) and BEL7402 (low expression) 
HCC cells were subjected to prolonged EGF treatment 
for 24 hours, with SMMC-7721 cells serving as a control. 
Interestingly, EGF-induced up-regulation of Tensin4 was 
only observed in BEL7402 but not PLC cells, possibly 
due to failure of increase in ERK1/2 activity in PLC cells 
(Figure 4C). Careful examination of the earlier time points 
of EGF treatment indicated that PLC cells did respond to 
the EGF stimulation, with the maximum ERK1/2 activity 
detected at 10 minutes, but it was followed by a quick 
reduction back to the basal level at 2 hours (Figure 4D, left 
panel). In contrast, the ERK1/2 activity was maintained 
at a high level in BEL7402 cells after EGF stimulation 
(Figure 4B, right panel). Consistently, the Tensin4 protein 
up-regulation in BEL7402 cells was coupled with the 
increase in the transcript level as in other cells (Figure 
4E). Besides the ERK1/2 activity, spatial changes in terms 
of an increase in nuclear accumulation of ERK1/2 and 
pERK1/2 started to be observable shortly after 10 minutes 
of EGF stimulation in SMMC-7721 cells (Figure 4F). A 
strong shifting of ERK1/2 localization from cytoplasm to 
nucleus was observed 60 minutes after the EGF treatment. 
Similar observation had also been confirmed in LO2 
cells (Supplementary Figure 4). The above observations 
suggested that EGF-induced Tensin4 up-regulation 
requires persistent ERK activation underlying ERK 
nuclear translocation.
EGF-induced Tensin4 up-regulation was 
associated with morphological changes
In addition to the underlying signaling changes, 
we observed significant morphological changes of 
the SMMC-7721 and LO2 cells upon EGF treatment. 
SMMC-7721 and LO2 cells changed from their uniform 
epithelial monolayer at the basal state to a scattered 
organization with an elongated, mesenchymal cell-
like shape. The cellular structural re-organization was 
visualized by the strong F-actin staining around the 
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Figure 4: EGF-induced Tensin4 up-regulation required persistent ERK activation underlying ERK nuclear 
translocation. A. SMMC-7721 cells were treated with EGF for the indicated durations and then released by washing twice with PBS 
followed by incubation for up to 8 hours. The cell lysates were then collected and subjected to Western blotting. B. SMMC-7721 and LO2 
cells were induced with EGF treatment plus pre-treatment or post-treatment with the MEK inhibitor U0126 at the indicated time points. All 
the samples were collected at 360 minutes (6 hours) and subjected to Western blotting for the indicated proteins. C. PLC, SMMC-7721 and 
BEL7402 cells with different basal Tensin4 expression level were treated with EGF for 24 hours. The cell lysates were then collected and 
subjected to Western blotting. The arrowhead highlights the induction of Tensin4 in BEL7402 cells with low basal Tensin4 expression. D. 
PLC and BEL7402 cells were treated with EGF at 40ng/ml for the indicated durations. The cell lysates were then collected and subjected 
for Western blotting. E. The Tensin4 mRNA expression level in BEL7402 cells after EGF induction at 6 and 24 hours were determined by 
qPCR comparing with the untreated control. F. SMMC-7721 cells subjected to EGF induction for the indicated time points were fixed and 
subjected to immunofluorescence detection for ERK1/2 and phospho-ERK1/2. The coverslips were counterstained with DAPI for nuclei. 
Scale bar: 10 μm.
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cell periphery and at the cell protrusions. The focal 
adhesions were also re-organized and became intensely 
stained at the actin protrusions (Figure 5, upper two 
panels). The dramatic cytoskeletal re-organization after 
EGF treatment in BEL7402 (Figure 5, lower panel) 
resembled the observations made in SMMC-7721 and 
LO2 cells. However, limited EGF-induced morphological 
changes were observed in PLC cells, probably due to 
the limited EGF-induced downstream ERK signaling 
with no observable Tensin4 induction (Figure 5, bottom 
panel). Taken together, EGF-treatment induced Tensin4 
expression through up-regulating ERK1/2 signaling, with 
associated cell morphology changes through modulation 
of the actin cytoskeleton.
Stable Tensin4 knockdown suppressed cell 
proliferation and EGF-induced cell migration
To assess the biological function in Tensin4 
expression in HCC cells, we established two stable 
shTensin4 knockdown clones (sequence -16 and -24) in 
SMMC-7721 cells by lentiviral transduction followed by 
puromycin selection. Successful Tensin4 knockdown were 
Figure 5: EGF induced morphological changes in cells with Tensin4 up-regulation. SMMC-7721, LO2, PLC and BEL7402 
cells were treated with EGF at a concentration of 40ng/ml for 24 hours. The cells were fixed and counterstained with phalloidin and DAPI 
for F-actin and cell nuclei. Scale bar: 10 μm.
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confirmed by Western blotting and compared with the 
non-targeted control (NTC) cells (Figure 5A). At the basal 
level (without EGF treatment), stable Tensin4 knockdown 
did not significantly alter the expression level and activity 
of EGFR and ERK1/2 (Figure 5A). Tensin4 knockdown 
cells remained sensitive to EGF, with up-regulation of the 
ERK1/2 activity after EGF treatment (Figure 5A), further 
confirming that Tensin4 is downstream of ERK.
Since Tensin4 expression in HCC cells was 
tightly regulated by EGF-MAPK signaling axis, which 
is strongly associated with cell growth and migratory 
ability, we queried whether Tensin4 knockdown might 
also have similar effects in HCC cells in these biological 
activities. In the cell proliferation assay, we observed 
that both Tensin4 knockdown SMMC-7721 cells showed 
a significant reduction in cell proliferation rate (Figure 
5B). In addition, these stable cells also displayed reduced 
morphological changes in response to EGF treatment, 
in accordance with the degree of Tensin4 knockdown 
efficiency (Figure 5C) and significant reduction in cell 
migration rate using the transwell assay with EGF as 
chemoattractant (Figure 5D). Taken together, these 
observations suggest that Tensin4, being a downstream 
target of ERK kinase, plays a significant role in promoting 
cell proliferation and migration in HCC cells due to Ras-
ERK signaling-mediated Tensin4 up-regulation (Figure 
5E).
DISCUSSION
Tensin4 was originally identified as the smallest 
Tensin family member and with tissue-specific expression 
in prostate and placenta [13]. However, it was later found 
that Tensin4 was also expressed in other normal human 
tissues such as prostate, breast, colon, lung and stomach 
at different basal levels [19]. Dysregulation of expression 
of Tensin4 has been suggested in various forms of human 
cancer [13, 16, 17, 19, 20, 23-26]; however, Tensin4 
expression has not yet been documented in HCC. 
In this study, we found that Tensin4 was expressed 
Figure 6: Stable Tensin4 knockdown suppressed HCC cell proliferation and EGF-induced cell migration. A. Establishment 
of two independent shTensin4 (-16 and -24) stable knockdown in SMMC-7721 cells by lentiviral transduction. The cell lysate of the stable 
knockdown cells and the corresponding non-targeted control (NTC) cells with or without the treatment of EGF were subjected to Western 
blotting for Tensin4 and various signaling components in EGF-ERK signaling. B. shTensin4 and the control SMMC-7721 cells were 
subjected to cell proliferation assay for eight days to assess the growth rate. shTensin4 stable cells proliferated significantly more slowly (p 
< 0.01; t-test). Data were obtained from three independent experiments. C. shTensin4 and control SMMC-7721 cells were subjected to EGF 
treatment for 12 hours, followed by immunofluorescence detection for F-actin with FITC-conjugated Phalloidin. Corresponding untreated 
control was also include (D) Scale bar: 10 μm. D. shTensin4 and the control SMMC-7721 cells were subjected to EGF-induced transwell 
migration assay for 12 hours. shTensin4 stable cells migrated significantly more slowly (p < 0.01; t-test) Data were obtained from three 
independent experiments. E. Schematic diagram illustrating the current findings on how growth factor such as EGF up-regulates Tensin4 
through Ras-MAPK signaling and its potential role in supporting cell migration.
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in human HCC cells, though the expression level was 
quite variable among the different cell lines. The Tensin4 
antibodies used in our study successfully detected 
endogenous Tensin4 protein in HCC cell lines, with an 
expected band size and a low non-specific background. 
We further used the same antibodies to performed 
immunohistochemistry for Tensin4 expression in human 
HCC tissue sections. In our cohort of 30 HCC cases, we 
found overexpression of Tensin4 in 43% of the tumors. 
In this study, we specifically focused on the mitogen 
expression regulation and functional role of Tesnin4 in 
HCC cell line model. 
Our current work provides a better understanding 
on both the molecular regulation and functional role 
of Tensin4 in HCC cells. Firstly, we systematically 
analyzed the subcellular localization of Tensin4 in HCC 
cells and demonstrated the requirement of SH2 domain 
plus the N-terminal region for its proper focal adhesion 
localization in cytoplasm. To our surprise, in addition to 
focal adhesion localization, truncation of the N-terminal 
region of Tensin4 was found to display a certain degree 
of nuclear staining. However, preliminary analysis of the 
primary amino acid sequence of Tensin4 did not identify 
any classically defined Nuclear Localization Signal (NLS). 
Tensin4 has been previously suggested to play tumorigenic 
role with β-catenin in the nucleus in colorectal cancer 
cells in vitro [20]. However, it is currently unclear how 
prevalent nuclear Tensin4 is and the exact mechanisms 
Tensin4 and β-catenin involved in driving tumorigenesis..
With the use of more HCC cell models, we 
defined several key requirements that are required for 
EGF-induced Tensin4 up-regulation, which included 
intact EGFR for EGF interaction, persistent ERK1/2 
activation after EGF stimulation, and a reasonable 
amount of basal expression of Tensin4. Furthermore, 
functional transcription and translational machineries are 
required to support the Tensin4 up-regulation. We clearly 
demonstrated that HCC cells with the above requirements 
had Tensin4 induction after EGF treatment, followed by 
significant morphological changes through cytoskeletal 
remodeling. Based on our work done so far, mitogen and 
cytokine other than EGF including hepatocyte growth 
factor (HGF) and interleukin-6 (IL-6) could not induce 
Tensin4 expression (Supplementary Figure 5), probably 
due to failure of stimulating persistent ERK activity. 
Other study has suggested that various growth factors 
and cytokines such as FGF and IL6 can induce Tensin4 
expression in human prostate and colon cell lines [27]. 
However, whether their actions are cell-type specific or 
not remains to be confirmed. We demonstrated an EGF-
induced ERK nuclear accumulation in SMMC-7721 and 
LO2 cells, which may probably be associated with Tensin4 
expression. However, the mode of interaction between 
the nuclear ERK and the transcription regulator(s) of 
Tensin4 remains to be explored and defined. Currently, no 
successful attempt has been made [28].
Using stable shTensin4 knockdown model in 
SMMC-7721, we demonstrated that Tensin4 was required 
for cell proliferation and EGF-induced cell migration in 
HCC cells, suggesting an oncogenic role of Tensin4 in 
HCC cells. The role of Tensin4 in cell proliferation has 
been controversial [11, 15, 16, 29]; our observation that 
Tensin4 affected SMMC-7721 cell proliferation upon 
knockdown may probably due to its high expression in 
SMMC-7721 cells. Although our results demonstrated 
the important role of Tensin4 in cell proliferation and 
migration, other molecular players that are potentially 
involved in Tensin4-associated function are not clearly 
understood. Previously, it has been suggested that integrin-
linked kinase (ILK) may work as a downstream target of 
Tensin4 to mediate its oncogenic function in colorectal 
cancer [23]. Although we have previously suggested the 
role of ILK in HCC cell migration [30], we did not find 
a reduction in the ILK expression level after Tensin4 
knockdown or an up-regulation in the ILK expression 
level after EGF stimulation (data not shown). The 
inconsistencies of the data regarding the signaling network 
linking up with Tensin4 functions again suggest its diverse 
roles in different tissue types through the utilization of 
different signaling pathways, and further investigation on 
this would be critical.
Taken together, our work has added an important 
piece of data to the role of Tensin4 in human HCC 
cells. Further functional exploration will help to address 
the actual molecular role of Tensin4 in mediating the 
biological effects in cell proliferation and migration. 
We look forward to the use of more relevant in vitro 
and in vivo models resembling the actual physiological 
environment to confirm the biological importance of 
Tensin4 in HCC and other human cancers.
MATERIALS AND METHODS
Plasmids
Tensin4 expression constructs using pEGFP-C1 
vector (BD Biosciences Clontech, Palo Alto, CA) were 
prepared by standard molecular cloning techniques and 
PCR amplification of the described fragments using the 
pEGFP-C1-cten as the template (a gift provided by Dr. 
Y. Yarden of Weizmann Institute of Science, Israel). 
The GFP-tagged expression vector, pEGFP-C1 carrying 
Tensin4 1-446 (∆SH2PTB), ∆447-547 (∆SH2), 1-580 
(∆PTB), 442-715 (SH2PTB), 442-566 (SH2), 567-715 
(PTB), 1-223, and 223-715 (233-stop), respectively, 
were constructed. All the DNA expression constructs 
were confirmed by DNA sequencing. shTensin4 and non-
targeted control (NTC; SHC002) lenti-viral based pLK0.1-
Puro constructs were purchased from Sigma (Sigma, St. 
Louis, MO, USA). The NTC construct carried a scrambled 
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sequence 5’-CAACAAGATGAAGAGCACCAA-3’ set 
out by RNAi consortium.
Cell culture, plasmid transfection, stable 
knockdown cells establishment
SMMC-7721, LO2 and BEL7402 cells were cultured 
in DMEM high-glucose medium supplemented with 10% 
fetal bovine serum, penicillin and streptomycin at 37oC 
with 5% CO2 in air. HLE and PLC cells were cultured 
in DMEM-low glucose medium and MEM medium 
supplemented with 10% fetal bovine serum, penicillin 
and streptomycin under the same conditions. For HLE cell 
transfection, cells were transfected with Lipofectamine 
2000 reagent (Invitrogen, Carlsbad, CA) as previously 
described [8]. Briefly, 1µg plasmid was mixed with 2.5µl 
Lipofectamine 2000 in 100µl serum free DMEM medium 
and incubated for 20 minutes at room temperature. The 
mixture was then added to HLE cells seeded on 12-well 
format (8X104cells/well) for 18 hours. For stable shRNA 
lenti-viral transduction, positive shTensin4 knockdown 
cells and shNon-Targeted Control (NTC) cells were 
selected with Puromycin at a concentration of 500ng/ml 
for 7 days after viral transduction. 
Epidermal growth factor (EGF) and inhibitor 
treatment
1.5x105 cells were seeded overnight in 12-well 
format and stimulated with 40ng/ml EGF (Cell Signaling 
Technology, Beverly, CA) in full growth medium for 
the indicated duration. Working concentration of 10µM 
MEK inhibitor U0126 (Cell Signaling Technology), 1µg/
ml transcriptional inhibitor Actinomycin D (Sigma) and 
50µg/ml translational inhibitor Cycloheximide (Sigma) 
were applied to the cell culture in specific experiment 
at the indicated time point and duration accordingly. All 
inhibitors were dissolved in DMSO.
Human HCC clinical samples
Human HCCs and their corresponding non-
tumorous liver samples of 30 randomly selected primary 
HCCs were obtained from patients with liver resection 
between 1991 and 2001 at Queen Mary Hospital, Hong 
Kong. All specimens were either snap-frozen in liquid 
nitrogen and stored at -80oC, or fixed in 10% formalin 
for paraffin embedding. The use of human specimens 
was approved by the institutional review board of the 
University of Hong Kong/Hospital Authority Hong Kong 
West Cluster (UW09-185). Among the 30 patients, 23 
were male and 7 female. The age ranged from 24-74 years 
(mean = 52.9 years). Twenty-four patients were serum 
positive for hepatitis B surface antigen (HBsAg); 6 were 
negative. The clinicopathological data of the patients are 
listed in Supplementary Table 1.
Real-time qPCR for Tensin4 expression
Specific forward and reverse primers for Tensin1, 
-2, -3 and -4 detection as described by Cao et al. 
[21] were employed to detect Tensin1, -2, -3 and -4 
expression in HCC cells with the use of SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, 
CA). Primer pairs 5’-aacacggatgagacctactgcat-3’ and 
5’-gggtgcggaagcagatgt-3’ were used for tubulin detection. 
qPCR reaction was performed on a Applied Biosystems 
7900HT Fast Real-Time PCR System. The relative 
comparison ∆∆CT method was used for gene expression 
analysis with tubulin used as internal control.
Protein lysate preparation and western blotting
Cell culture in 12-well format was washed once 
with PBS and subjected to the direct SDS-lysis with 60ul 
standard Laemmli sample buffer with DTT. The whole 
cell lysate were boiled for 10 minutes. One-tenth of the 
cell lysate was subjected to 10% SDS-PAGE analysis. 
Most of the immunoblotting detection (EGFR, phospho-
ERK1/2 Thr202/Tyr204, ERK1/2, phospho-Akt Ser473) 
was performed using antibodies from Cell Signaling 
Technology at a dilution of 1:1000 in 4% BSA/TBST 
as suggested by the manufacturer. Other proteins were 
detected with the use of anti-Tensin4 (ab82178) antibody 
(1:500, Abcam, Cambridge, MA, USA) in 4% BSA/TBST, 
anti-GFP antibody (1:1000, Santa Cruz Biotechnology), 
and anti-tubulin antibody (1:5000, Sigma) in 4% milk/
TBST respectively.
Immunofluorescence microscopy and 
immunohistochemistry
Cells seeded on coverslips with were fixed with 
4% paraformaldehyde in PBS for 15 minutes and then 
permeabilized with 0.1% Triton-X-100 in PBS for 10 
minutes, followed by blocking with 3% bovine serum 
albumin in PBS for 20 minutes at room temperature. 
The blocked coverslips were stained with anti-paxillin 
antibody (1:400, EMD Millipore, Billerica, MA), followed 
by AlexaFluor-594-conjugated secondary antibody 
(Invitrogen) to visualize focal adhesions. The F-actin 
and nuclei were visualized by TRITC-labeled phalloidin 
and DAPI (Sigma). For immunofluorescence detection 
for ERK1/2 (1:50, ERK1/2 antibody) and pERK1/2 
(1:500, pERK1/2 antibody), methanol permeabilization 
(IF Methanol-perm) was performed accordingly with 
the protocol set out by the manufacturer (Cell Signaling 
Technology). The processed coverslips were mounted 
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in Vectashield anti-fade mounting medium (Vector 
Laboratories, Burlingame, CA) Images were captured by 
a Carl Zeiss LSM700 laser scanning confocal microscope. 
Immunohistochemistry was performed on formalin-fixed, 
paraffin-embedded sections from resected livers from 
HCC patients, using rabbit polyclonal antibody against 
IHC capable anti-Tensin4 (ab82178) antibody (Abcam) at 
1:50 dilution.
Cell proliferation assay
1x103 cells of Tensin4 knockdown and control cells 
were seeded overnight in triplicate in 24-well format 
and cultured for 8 days. The total number of cells were 
counted and recorded every two days with the use of the 
Z1 particle counter (Beckman Coulter, Fullerton, CA).
Transwell migration assay
1x105 SMMC-7721 cells in 100ul serum-free 
medium were seeded on the top chamber of the transwell 
and stimulated to migrate with 20ng/ml EGF added at 
the lower chamber for 12 hours. The migrated cells were 
fixed with methanol and stained with 0.04% crystal violet 
solution for 20 minutes. The number of migrated cells was 
counted and recorded accordingly.
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